Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 5Other solid neoplasm 2Genitourinary 2Tumor-Agnostic 1Other hematologic neoplasm 1NET 1Lymphoid 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 93Nivolumab 61Docetaxel 55Cyclophosphamide 49enzalutamide 44Magnetic Resonance Spectroscopy 33Ipilimumab 33Gemcitabine 32Abiraterone Acetate 30Prednisone 29fludarabine 28Everolimus 27Paclitaxel 25Cisplatin 24Radiotherapy 23Carboplatin 23Sunitinib 22cabozantinib 21atezolizumab 20Radiosurgery 20Specimen Handling 19Sorafenib 18Bevacizumab 18pazopanib 17bicalutamide 17abiraterone 17Biopsy 15temsirolimus 14darolutamide 14apalutamide 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × dactolisib × Genitourinary × Clear all
NCT01482156 2020-12-21

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
46 enrolled
BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell

NCT01634061 2020-12-09

Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients

Novartis

Phase 1 Completed
43 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡